Inhibitors of cyclin dependent kinases: Useful targets for cancer treatment

Current Cancer Drug Targets

Volumn 8, Issue 1, 2008, Pages 53-75

  Sapra Sharma, P ^a   Sharma, R ^a   Tyagi, R ^a  

^a CSSS (P G) College   (India)

Author keywords

Anticancer agents; Apoptosis; Cell cycle; CKIs; Cyclin dependent kinase; Small molecule inhibitors

Indexed keywords

7 HYDROXYSTAUROSPORINE; ACETOPHTHALIDIN; ADENOSINE TRIPHOSPHATE; ALOISINE; ANTINEOPLASTIC AGENT; BUTYROLACTONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVONOID; HYDRAZONE DERIVATIVE; HYMENIALDISINE; INDIRUBIN; INDISULAM; INDOLE DERIVATIVE; PAULLONE; PAULLONE DERIVATIVE; PHTHALIDE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SELENIUM DERIVATIVE; STAUROSPORINE; STAUROSPORINE DERIVATIVE; THIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 39049126024     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908783497131     Document Type: Review

References (196)

1. Foye, W. O. Ed. Cancer Chemotherapeutic Agent American Chemical Society: Washington DC, 1995.
2. Morgan, D. O. Principles of CDK Regulation. Nature 1995, 374(6518), 131-134.
3. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanan, S. The Protein Kinase Complement of the Human Genome. Science 2002, 298(5600), 1912-1934.
4. Harper, J. W.; Adams, P. D. Cyclin-Dependent Kinases. Chem. Rev. 2001, 101(8), 2511-2526.
5. Hunter, T.; Pines, J. Cyclins and Cancer. II: Cyclin D and CDK Inhibitors Come of Age. Cell 1994, 79(4), 573-582.
6. Legraverend, M.; Grierson, D. S. The Purines: Potent and Versatile Small Molecule Inhibitors and Modulators of Key Biological Targets. Bioorg. Med. Chem. 2006, 14(12), 3987-4006.
7. Vermeulen, K.; Van Bockstaele, D. R.; Berneman, Z. N. The Cell Cycle: a Review of Regulation, Deregulation and Therapeutic Targets in Cancer. Cell Prolif. 2003, 36(3), 131-149.
8. Huwe, A.; Mazitschek, R.; Giannis, A. Small Molecules as Inhibitors of Cyclin-Dependent Kinases. Angew. Chem., Int. Ed. 2003, 42(19), 2122-2138.
9. Noble, M. E. M.; Endicott, J. A.; Johnson, L. N. Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science 2004, 303(5665), 1800-1805.
10. Bridges, A. J. Chemical Inhibitors of Protein Kinases. Chem. Rev. 2001, 101(8), 2541-2571.
11. Force, T.; Kuida, K.; Namchuk, M.; Parang, K.; Kyriakis, J. M. Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease. Circulation 2004, 109, 1196-1205.
12. Heady, L.; Fernandez-Serra, M.; Mancera, R. L.; Joyce, S.; Venkitaraman, A. R.; Artacho, E.; Skylaris, C. -K.; Ciacchi, L. C.; Payne, M. C. Novel Structural Features of CDK Inhibition Revealed by an ab initio Computational Method Combined with Dynamic Simulations. J. Med. Chem. 2006, 49(17), 5141-5153.
13. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The Specificities of Protein Kinase Inhibitors: an Update. Biochem. J. 2003, 371(Pt. 1), 199-204.
14. Park, H.; Yeom, M. S.; Lee, S. Loop Flexibility and Solvent Dynamics as Determinants for the Selective Inhibition of Cyclin-Dependent Kinase 4: Comparative Molecular Dynamics Simulation Studies of CDK2 and CDK4. ChemBioChem 2004, 5(12), 1662-1672.
15. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S. Crystallographic Approach to Identification of Cyclin-Dependent Kinase 4 (CDK4)-Specific Inhibitors by Using CDK4 Mimic CDK2 Protein. J. Biol. Chem. 2001, 276(29), 27548-27554.
16. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation. J. Med. Chem. 2000, 43(1), 1-18.
17. Nakayama, K.; Nakayama K. Cip/Kip Cyclin-Dependent Kinase Inhibitors: Brakes of the Cell Cycle Engine During Development. Bioessays 1998, 20(12), 1020-1029.
18. Chim, C. S.; Fung, T. K.; Wong, K. F.; Lau, J. S.; Law, M.; Liang, R. Methylation of INK4 and CIP/KIP Families of Cyclin-Dependent Kinase Inhibitor in Chronic Lymphocytic Leukaemia in Chinese Patients. J. Clin. Pathol. 2006, 59(9), 921-926.
19. Maddika, S.; Ande, S. R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K. D.; Wiechec, E.; Los, M. Cell Survival, Cell Death and Cell Cycle Pathways are Interconnected: Implications for Cancer Therapy. Drug Resist. Updat. 2007, 10(1-2), 13-29.
20. Peter, M.; Herskowitz, I. Joining the Complex: Cyclin-Dependent Kinase Inhibitory Proteins and the Cell Cycle. Cell 1994, 79(2), 181-184.
21. Mainprize, T. G.; Taylor, M. D.; Rutka, J. T.; Dirks, P. B. Cip/Kip Cell-Cycle Inhibitors: a Neuro-Oncological Perspective. J. Neurooncol. 2001, 51(3), 205-218.
22. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a Universal Inhibitor of Cyclin Kinases. Nature 1993, 366(6456), 701-704.
23. Janicke, R. U.; Sohn, D.; Essmann, F.; Schulze-Osthoff, K. The Multiple Battles Fought by Anti-Apoptotic p21. Cell Cycle 2007, 6(4), 407-413.
24. Kip1 Cyclin-Dependent Kinase Inhibitor Bound to the Cyclin A-CDK2 Complex. Nature 1996, 382(6589), 325-331.
25. Hall, M.; Bates, S.; Peters, G. Evidence for Different Modes of Action of Cyclin Dependent Kinase Inhibitors: p15 and p16 Bind to Kinases, p21 and p27 Bind to Cyclins. Oncogene 1995, 11(8), 1581-1588.
26. Cip1. Genes Dev. 1998, 12(24), 3882-3888.
27. Gao, C. Y.; Zalenka, P. S. Cyclins, Cyclin-Dependent Kinases and Differentiation. Bioessays 1997, 19(4), 307-315.
28. Carnero, A.; Hannon, G. J. In Cyclin Dependent Kinase (CDK) Inhibitors; Vogt, P. K.; Reed, S. I.; Eds.; Springer: New York, 1997, pp. 43-55.
29. INK4B/MTS2-Related CDK6 Inhibitor, Correlates with Wild-Type pRb Function. Genes Dev. 1994, 8(24), 2939-2952.
30. INK4B is a Potential Effector of TGFβ-Induced Cell Cycle Arrest. Nature 1994, 371(6494), 257-261.
31. Reynisdottir, I.; Polyak, K.; Iavarone, A.; Massague, J. Kip/Cip and INK4 CDK Inhibitors Cooperate to Induce Cell Cycle Arrest in Response to TFGβ. Genes Dev. 1995, 9(15), 1831-1845.
32. INK4C as an Inhibitor of Cyclin-Dependent Kinase 4. Biochemistry 2000, 39(4), 649-657.
33. INK4d. Nature 1998, 395(6699), 244-250.
34. Kim, S. H. Structure-Based Inhibitor Design for CDK2, a Cell Cycle Controlling Protein Kinase. Pure Appl. Chem. 1998, 70(3), 555-565.
35. Furusaki, A.; Hashiba, N.; Matsumoto, T.; Hirano, A.; Iwai, Y.; Omura, S. The Crystal and Molecular Structure of Staurosporine, a New Alkaloid from a Streptomyces Strain. Bull. Chem. Soc. Jpn. 1982, 55, 3681-3685.
36. Meijer, L. Chemical Inhibitors of Cyclin-Dependent Kinases. Trends Cell. Biol. 1996, 6(10), 393-397.
37. Meijer, L. Chemical Inhibitors of Cyclin-Dependent Kinases. In Progress in Cell Cycle Research; Meijer, L., Guidet, S., Tung, H. Y. L., Eds.; Plenum Press: New York, 1995, pp. 351-361.
38. Harmalkar, M. N.; Shirsat, N. V. Staurosporine-Induced Growth Inhibition of Glioma Cells is Accompanied by Altered Expression of Cyclins, CDKs and CDK Inhibitors. Neurochem. Res. 2006, 31(5), 685-692.
39. Grosios, K. UCN-01 Kyowa Hakko Kogyo Co. Curr. Opin. Investig. Drugs 2001, 2(2), 287-297.
40. Senderowicz, A. M. Inhibitors of Cyclin-Dependent Kinase Modulators for Cancer Therapy. Prog. Drug Res. 2005, 63, 183-206.
41. Cartee, L.; Sankala, H.; Davis, C.; Smith, R.; Maggio, S.; Lin, P. S.; Dent, P.; Grant, S. 7-Hydroxystaurosporine (UCN-01) and Ionizing Radiation Combine to Inhibit the Growth of Bcl-2-Overexpressing U937 Leukemia Cells through a Non-Apoptotic Mechanism. Int. J. Oncol. 2002, 21(2), 351-359.
42. Abe, S.; Kubota, T.; Otani, Y.; Furukawa, T.; Watanabe, M.; Kumai, K.; Kitajima, M. Sensitivity of UCN-01 Lies in the Balance of CDK2 Kinase and p21. Gan To Kagaku Ryoho. 2000, 27(8), 1260-1266.
43. Chin, L. S.; Murray, S. F.; Doherty, P. F.; Singh, S. K. K252a Induces Cell Cycle Arrest and Apoptosis by Inhibiting Cdc2 and Cdc25c. Cancer Invest. 1999, 17(6), 391-395.
44. WAF1. Oncol. Rep. 2005, 14(1), 141-143.
45. Link, J. T.; Raghavan, S.; Gallant, M.; Danishefsky, S. J.; Chou, T. C.; Ballas, L. M. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles. J. Am. Chem. Soc. 1996, 118(12), 2825-2842.
46. Pereira, E. R.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Severe, D.; Riou, J. -F.; Fabbro, D.; Meyer, T. Structure-Activity Relationships in a Series of Substituted Indolocarbazoles: Topoisomerase I and Protein Kinase C Inhibition and Antitumoral and Antimicrobial Properties. J. Med. Chem. 1996, 39(22), 4471-4477.
47. Wood, J. L.; Stoltz, B. M.; Goodman, S. N.; Onwueme, K. Design and Implementation of an Efficient Synthetic Approach to Pyranosylated Indolocarbazoles: Total Synthesis of (+)-RK286c, (+)-MLR-52, (+)-Staurosporine, and (-)-TAN-1030a. J. Am. Chem. Soc. 1997, 119(41), 9652-9661.
48. Kuo, P. C.; Liu, H. F.; Chao, J. I. Survivin and p53 Modulate Quercetin-Induced Cell Growth Inhibition and Apoptosis in Human Lung Carcinoma Cells. J. Biol. Chem. 2004, 279(53), 55875-55885.
49. Vijayababu, M. R.; Kanagaraj, P.; Arunkumar, A.; Ilangovan, R.; Aruldhas, M. M.; Arunakaran, J. Quercetin-Induced Growth Inhibition and Cell Death in Prostatic Carcinoma Cells (PC-3) are Associated with Increase in p21 and Hypophosphorylated Retinoblastoma Proteins Expression. J. Cancer Res. Clin. Oncol. 2005, 131(11), 765-771.
50. Wirger A.; Perabo F. G.; Burgemeister, S.; Haase, L.; Schmidt, D. H.; Doehn, C.; Mueller, S. C.; Jocham, D. Flavopiridol, an Inhibitor of Cyclin-Dependent Kinases, Induces Growth Inhibition and Apoptosis in Bladder Cancer Cells in vitro and in vivo. Anticancer Res. 2005, 25(6B), 4341-4347.
51. Morris, D. G.; Bramwell, V. H.; Turcotte, R.; Figueredo, A. T.; Blackstein, M. E.; Verma, S.; Matthews, S.; Eisenhauer, E. A. A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. Sarcoma 2006, 1, 1-7.
52. Sedlacek, H. H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewich, M.; Parker, B.; Carlson, B.; Smith, A. Flavopiridol (L86-8275; NSC 649890), a New Kinase Inhibitor for Tumor Therapy. Int. J. Oncol. 1996, 9, 1143-1168.
53. Losiewicz, M. D.; Carlson, B. A.; Kaur, G.; Sausville, E. A.; Worland, P. J. Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275. Biochem. Biophys. Res. Commun. 1994, 201(2), 589-595.
54. Czech, J.; Hoffman, D.; Naik, R.; Sedlacek, H. Antitumoral Activity of Flavone L86-8275. Int. J. Oncol. 1995, 6, 31-36.
55. Bible, K. C.; Kaufmann, S. H. Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: the Importance of Sequence of Administration. Cancer Res. 1997, 57(16), 3375-3380.
56. Ahn, Y. M.; Vogeti, L.; Liu, C. J.; Santhapuram, H. K.; White, J. M.; Vasandani, V.; Mitscher, L. A.; Lushington, G. H.; Hanson, P. R.; Powell, D. R.; Himes, R. H.; Roby, K. F.; Ye, Q.; Georg, G. I. Design, Synthesis, and Antiproliferative and CDK2-Cyclin a Inhibitory Activity of Novel Flavopiridol Analogues. Bioorg. Med. Chem. 2007, 15(2), 702-713.
57. Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effect. J. Med. Chem. 2000, 43(22), 4126-4134.
58. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangreve-linghe, E.; Furet, P. Structure-Based Design and Synthesis of 2-Benzylidene-benzofuran-3-ones as Flavopiridol Mimics. J. Med. Chem. 2002, 45(9), 1741-1747.
59. Lu, X.; Jung, J.; Cho, H. J.; Lim, D. Y.; Lee, H. S.; Chun, H. S.; Kwon, D. Y.; Park, J. H. Fisetin Inhibits the Activities of Cyclin-Dependent Kinases Leading to Cell Cycle Arrest in HT-29 Human Colon Cancer Cells. J. Nutr. 2005, 135(12), 2884-2890.
60. Lu, H.; Chang, D. J.; Baratte, B.; Meijer, L.; Schulze-Gahmen, S. Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin. J. Med. Chem. 2005, 48(3), 737-743.
61. Lee, A. J.; Park, T.; Jeong, S.; Kim, K. H.; Hong, C. 3-Hydroxychromones as Cyclin-Dependent Kinase Inhibitors: Synthesis and Biological Evaluation. Bioorg. Med. Chem. Lett. 2007, 17(5), 1284-1287.
62. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; Detivaud, L.; LeClerc, S.; Meijer, L. Inhibition of Cyclin Dependent Kinases by Purine Analogues. Eur. J. Biochem. 1994, 224(2), 771-786.
63. Raynaud, F. I.; Whittaker, S. R.; Fischer, P. M.; McClue, S.; Walton, M. I.; Barrie, S. E.; Garrett, M. D.; Rogers, P.; Clarke, S. J.; Kelland, L. R.; Valenti, M.; Brunton, L.; Eccles, S.; Lane, D. P.; Workman, P. In vitro and in vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomucine, Bohemine and CYC202. Clin. Cancer Res. 2005, 11(13), 4875-4887.
64. Boutis, A.; Papazisis, K.; Pistevou-Gompaki. K.; Lambropoulos, A.; Sofroniadis, I.; Papageorgiou, A.; Destouni, E.; Kortsaris, A. Cyclin-Dependent Kinase (CDK) Inhibitor Olomoucine Enhances Gamma-Irradiation-Induced Apoptosis and Cell Cycle Arrest in Raji Cells. Anticancer Res. 2006, 26(5A), 3493-3498.
65. Krystof, V.; Lenobel, R.; Havlicek, L.; Kuzma, M.; Strnad, M. Synthesis and Biological Activity of Olomoucine II. Bioorg. Med. Chem. Lett. 2002, 12(22), 3283-3286.
66. Krystof, V.; McNae, I. W.; Walkinshaw, M. D.; Fischer, P. M.; Muller, P.; Vojtesek, B.; Orsag, M.; Havlicek, L.; Strnad, M. Antiproliferative Activity of Olomoucine II, a Novel 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor. Cell. Mol. Life Sci. 2005, 62(15), 1763-1771.
67. Bach, S.; Knockaert, M.; Reinhardt, J.; Lozach, O.; Schmitt, S.; Baratte, B.; Koken, M.; Coburn, S. P.; Tang, L.; Jiang, T.; Liang, D. C.; Galons, H.; Dierick, J. F.; Pinna, L. A.; Meggio, F.; Totzke, F.; Schachtele, C.; Lerman, A. S.; Carnero, A.; Wan, Y.; Gray, N.; Meijer, L. Roscovitine Targets, Protein Kinases and Pyridoxal Kinase. J. Biol. Chem. 2005, 280(35), 31208-31219.
68. Mapelli, M.; Massimiliano, L.; Crovace, C.; Seeliger, M. A.; Tsai, L. -H.; Meijer, L.; Musacchio, A. Mechanism of CDK5/p25 Binding by CDK Inhibitors. J. Med. Chem. 2005, 48(3), 671-679.
69. MacCallum, D. E.; Melville, J.; Frame, S.; Watt, K.; Anderson, S.; Gianella-Borradori, A.; Lane, D. P.; Green, S. R. Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-Regulation of Mcl-1. Cancer Res. 2005, 65(12), 5399-5407.
70. Coley, H. M.; Shotton, C. F.; Thomas, H. Seliciclib (CYC202; RRoscovitine) in Combination with Cytotoxic Agents in Human Uterine Sarcoma Cell Lines. Anticancer Res. 2007, 27(1A), 273-278.
71. Meijer, L.; Raymond, E. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials. Acc. Chem. Res. 2003, 36(6), 417-425.
72. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. Proteins 1995, 22(4), 378-391.
73. Kriz, Z.; Otyepka, M.; Bartova, I.; Koca, J. Analysis of CDK2 Active-Site Hydration: a Method to Design New Inhibitors. Proteins 2004, 55(2), 258-274.
74. Alberio, R.; Kubelka, M.; Zakhartchenko, V.; Hajduch, M.; Wolf, E.; Motlik, J. Activation of Bovine Oocytes by Specific Inhibition of Cyclin-Dependent Kinases. Mol. Reprod. Dev. 2000, 55(4), 422-432.
75. Adona, P. R.; Lima Verde Leal, C. Meiotic Inhibition with Different Cyclin-Dependent Kinase Inhibitors in Bovine Oocytes and its Effects on Maturation and Embryo Development. Zygote 2004, 12(3), 197-204.
76. Raynaud, F. I.; Fischer, P. M.; Nutley, B. P.; Goddard, P. M.; Lane, D. P.; Workman, P. Cassette Dosing Pharmacokinetics of a Library of 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase 2 Inhibitors Prepared by Parallel Synthesis. Mol. Cancer Ther. 2004, 3(3), 353-362.
77. Gray, N. S.; Wodicka, L.; Thunnissen, A. -M. W. H.; Norman, T. C.; Kwon S.; Espinoza, H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. -H.; Lockhart, D. J.; Schultz, P. G. Exploiting Chemical Libraries, Structure and Genomics in the Search for Kinase Inhibitors. Science 1998, 281(5376), 533-538.
78. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norman, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Shiffman, D. CVT-313, a Specific and Potent Inhibitor of CDK2 that Prevents Neointimal Proliferation. J. Biol. Chem. 1997, 272(46), 29207-29211.
79. Legraverend, M.; Ludwig, O.; Bisagni, E.; LeClerc, S.; Meijer, L. Synthesis of C2 Alkynylated Purines, a New Family of Potent Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 1998, 8(7), 793-798.
80. Vandromme, L; Piguel, S.; Lozach, O.; Meijer, L.; Legraverend, M.; Griersona, D. S. Suzuki-Type Pd(0) Coupling Reactions in the Synthesis of 2-Arylpurines as CDK Inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(12), 3144-3146.
81. 6-Cyclohexylmethyl-guanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2. J. Med. Chem. 2004, 47(15), 3710-3722.
82. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-Based Design of a Potent Purine-Based Cyclin-Dependent Kinase Inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
83. Dumont, J. A.; Bitonti, A. J.; Borcherding, D. R.; Peet, N. P.; Munson, H. R.; Shum Patrick, W. K. 9-Disubstituted-2-[trans-(4-aminocyclohexyl)] aminopurines, WO 99/43676, September 2, 1999.
84. Trova, M. P. Heterocycle Substituted Purine Derivatives as Potent Antiproliferative Agents. WO 03/022805 A2, March 20, 2003.
85. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S. H. Crystal Structure of Human Cyclin-Dependent Kinase 2 in Complex with the Adenine-Derived Inhibitor H717. J. Med. Chem. 2001, 44(4), 524-530.
86. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and Application of Functionally Diverse 2,6,9-Trisubstituted Purine Libraries as CDK Inhibitors. Chem. Biol. 1999, 6(6), 361-375.
87. Furet, P. X-ray Crystallographic Studies of CDK2, a Basis for Cyclin-Dependent Kinase Inhibitor Design in Anti-Cancer Drug Research. Curr. Med. Chem. Anti Cancer Agents 2003, 3(1), 15-23.
88. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological Inhibitors of Cyclin-Dependent Kinases. Trends Pharmacol. Sci. 2002, 23(9), 417-425.
89. Imbach, P.; Capraro, H. G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors. Bioorg. Med. Chem. Lett. 1999, 9(1), 91-96.
90. Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Schiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and Activity of 2,6,9-Trisubstituted Purines. Bioorg. Med. Chem. Lett. 1997, 7(21), 2697-2702.
91. Travnicek, Z.; Krystof, V.; Sipl, M. Zinc(II) Complexes with Potent Cyclin-Dependent Kinase Inhibitors Derived from 6-Benzylaminopurine: Synthesis, Characterization, X-ray Structures and Biological Activity. J. Inorg. Biochem. 2006, 100(2), 214-225.
92. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T. Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. J. Med. Chem. 2001, 44(25), 4339-4358.
93. Singh, S. K.; Dessalew, N.; Bharatam, P. V. 3D-QSAR CoMFA Study on Oxindole Derivatives as Cyclin Dependent Kinase 1 (CDK1) and Cyclin Dependent Kinase 2 (CDK2) Inhibitors. Med. Chem. 2007, 3(1), 75-84.
94. Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun., L.; Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A Novel CDK2-Selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma cells. Cancer Res. 2001, 61(16), 6170-6177.
95. Gao, N.; Kramer, L.; Rahmani, M.; Dent, P.; Grant, S. The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 Through a Transcriptional Mechanism. Mol. Pharmacol. 2006, 70(2), 645-655.
96. Guengerich, F. P.; Sorrells, J. L.; Schmitt, S.; Krauser, J. A.; Aryal, P.; Meijer, L. Generation of New Protein Kinase Inhibitors Utilizing Cytochrome P450 Mutant Enzyme for Indigoid Synthesis. J. Med. Chem. 2004, 47(12), 3236-3241.
97. Zhu, G.; Conner, S. E.; Zhou, X.; Shih, C.; Li, T.; Anderson, B. D.; Brooks, H. B.; Campbell, R. M.; Considine, E.; Dempsey, J. A.; Faul, M. M.; Ogg, F. C.; Patel, B.; Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A. Synthesis, Structure-Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitor. J. Med. Chem. 2003, 46(11), 2027-2030.
98. McCombie, S. W.; Bishop, R. W.; Carr, D.; Dobek, E.; Kirkup, M. P.; Kirschmeier, P.; Lin, S.-I.; Petrin, J.; Rosinski, K.; Shankar, B. B.; Wilson, O. Indolocarbazoles 1: Total Synthesis and Protein Kinase Inhibiting Characteristics of Compounds Related to K-252c. Bioorg. Med. Chem. Lett. 1993, 3(8), 1537-1542.
99. Sanchez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H. B.; Patel, B. K.; Schultz, R. M.; DeHahn, T. B.; Spencer, C. D.; Watkins, S. A.; Ogg, C. A.; Considine, E.; Dempsey, J. A.; Zhang, F. Studies on Cyclin-Dependent Kinase Inhibitors: Indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus Bisindolylmaleimides. Bioorg. Med. Chem. Lett. 2003, 13(21), 3841-3846.
100. Lane, D. P. Cyclin Dependent Kinase Binding Compound. WO 97/11174, March 27, 1997.
101. Sasaki, S.; Hashimuto, T.; Obana, N.; Yasuda, H.; Uehara, Y.; Maeda, M. Design of New Inhibitors for Cdc2 Kinase Based on Multiple Pseudosubstrate Structure. Bioorg. Med. Chem. Lett. 1998, 8(9), 1019-1022.
102. Misra, R. N.; Rawlins, D. B.; Xiao, H. -Y.; Shan, W.; Bursuker, I.; Kellar, K. A.; Mulheron,y, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball,y, D. S.; Webster, K. R. 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases. Bioorg. Med. Chem. Lett. 2003, 13(6), 1133-1136.
103. Duca, J. S.; Madison, V. S. Insights from ab initio Quantum Chemical Calculations into the Preferred Tautomeric Forms and Binding Affinities to CDK2 of Substituted Pyrazolopyridines. Biopolymers 2005, 80(2-3), 312-318.
104. Misra, R. N.; Rawlins, D. B.; Xiao, H.-Y.; Shan, W.; Bursuker, I.; Kellar, K. A.; Mulheron,y, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball,y, D. S.; Webster, K. R. 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases: Highly Potent 2,6-Difluorophenacyl Analogues. Bioorg. Med. Chem. Lett. 2003, 13(14), 2405-2408.
105. Huang, S.; Lin, R.; Yu, Y.; Lu, Y.; Connolly, P. J.; Chiu, G.; Li, S.; Emanuel, S. L.; Middleton, S. A. Synthesis of 3-(1H-Benzimidazol-2-yl)-5- isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a Potent CDK1 Inhibitor. Bioorg. Med. Chem. Lett. 2007, 17(5), 1243-1245.
106. Byths, K. F.; Geh, C.; Forder, C. L.; Oakes, S. E.; Thomas, A. P. The Cellular Phenotype of AZ703, a Novel Selective Imidazo[1,2-a]pyridine Cyclin-Dependent Kinase Inhibitor. Mol. Cancer Ther. 2006, 5(3), 655-664.
107. Cai, D.; Byth, K. F.; Shapiro, G. I. AZ703, an Imidazo[1,2-a]pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9. Cancer Res. 2006, 66(1), 435-444.
108. Dweyer, M. P.; Guzi, T. J.; Paruch, K.; Doll, R. J.; Keertikar, K. M.; Girijavallabham, V. M. Novel Pyrazolopyridines as Cyclin Dependent Kinase Inhibitors. WO 2004/026872 A1, April 1, 2004.
109. Kuo, G. H.; Deangelis, A.; Emanuel, S.; Wang, A.; Zhang, Y.; Connolly, P. J.; Chen, X.; Gruninger, R. H.; Rugg, C.; Fuentes-Pesquera, A.; Middleton, S. A.; Jolliffe, L.; Murray, W. V. Synthesis and Identification of [1,3,5]Triazine-Pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors. J. Med. Chem. 2005, 48(14), 4535-4546.
110. Tu, S.; Zhang, J.; Zhu, X.; Xu, J.; Zang, Y.; Wang, Q.; Jia, R.; Jiang, B.; Zhang, J. New Potential Inhibitors of Cyclin-Dependent Kinase 4: Design and Synthesis of Pyrido[2,3-d]pyrimidine Derivatives Under Microwave Irradition. Bioorg. Med. Chem. Lett. 2006, 16(13), 3578-3581.
111. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido-[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases. J. Med. Chem. 2000, 43, 4606-4616.
112. VanderWel, S. N.; Harvey, P. J.; McNamara, D. J.; Repine, J. T.; Keller, P. R.; Quin J. III; Booth, R. J.; Elliott, W. L.; Dobrusin, E. M.; Fry, D. W.; Toogood, P. L. Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4. J. Med. Chem. 2005, 48(7), 2371-2387.
113. Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6. J. Med. Chem. 2005, 48(7), 2388-2406.
114. Markwalder, J. A.; Arnone, M. R.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Chang, C. H.; Cox, S. S.; Czerniak, P. M.; Dean, C. L.; Doleniak, D.; Grafstrom, R.; Harrison, B. A.; Kaltenbach, R. F. III.; Nugiel, D.; Rosi, K. A.; Sherk, S. R.; Sisk, L. M.; Stouten, P.; Trainor, G. L.; Worland, P.; Seitz, S. P. Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[ 3,4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases. J. Med. Chem. 2004, 47(24), 5894-5911.
115. Markwalder, J. A.; Seitz, S. P.; Sherk, S. R. 6-Substituted Pyrazolo(3,4-d)pyrimidin-4-ones Useful as Cyclin Dependent Kinase Inhibitors. WO 00/21926, April 20, 2000.
116. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S. Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity. J. Med. Chem. 2004, 47(7), 1662-1675.
117. Newcombe, N. J.; Thomas, A. P. Pyrimidine Compounds. WO 03/076433, September 18, 2003.
118. Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 1: Identification and Optimisation of Substituted 4,6-Bis Anilino Pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13(18), 2955-2960.
119. Harris, P. A.; Jung, D. K.; Peel, M. R.; Reno, M. J.; Rheault, T. R.; Stanford, J. B.; Stevens, K. L.; Veal, J. M. Pyrazolopyridazine Derivatives. WO 03/051886 A1, June 26, 2003.
120. Huang, S.; Li, R.; Connolly, P. J.; Emanuel, S.; Middleton, S. A. Synthesis of 2-Amino-4-(7-azaindol-3-yl)pyrimidines as Cyclin Dependent Kinase 1 (CDK1) Inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(18), 4818-4821.
121. Richardson, C. M.; Williamson, D. S.; Parratt, M. J.; Borgognoni, J.; Cansfield, A. D.; Dokurno, P.; Francis, G. L.; Howes, R.; Moore, J. D.; Murray, J. B.; Robertson, A.; Surgenor, A. E.; Torrance, C. J. Triazolo[1,5-a] pyrimidines as Novel CDK2 Inhibitors: Protein Structure-Guided Design and SAR. Bioorg. Med. Chem. Lett. 2006, 16(5), 1353-1357.
122. Sondhi, S. M.; Goyal, R. N.; Lahoti, A. M.; Singh, N.; Shukla, R.; Raghubir, R. Synthesis and Biological Evaluation of 2-Thiopyrimidine Derivatives. Bioorg. Med. Chem. 2005, 13(9), 3185-3195.
123. Pease, E. J.; Breault, G. A.; Bradbury, R. H. Pyrimidine Compounds. WO 01/64653 A1, September 7, 2001.
124. Boschelli, D. H.; Dobrusin, E. M.; Doherty, A. M.; Fattacy, A.; Fry, D. W.; Barvian, M. R.; Kallmeyer, S. T.; Wu, Z. Pyrido[2,3-d]pyrimidines and 4-Aminopyrimidines as Inhibitors of Cellular Proliferation. WO 98/33798, August 6, 1998.
125. Pease, E. J.; Breault, G. A.; Williams, E. J.; Bradbury, R. H.; Morris, J. J. 2,4-Di (hetero-)arylamino(-oxy)-5-substutited Pyrimidines as Antineoplastic Agents. WO 01/64655 A1, September 7, 2001.
126. Mesguiche, V.; Parsons, R. J.; Arris, C. E.; Bentley, J.; Boyle, F. T.; Curtin, N. J.; Davies, T. G.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Newell, D. R.; Noble, M. E. M.; Wang, L. Z.; Hardcastle, I. R. 4-Alkoxy-2,6-diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13(2), 217-222.
127. Newcombe, N. J.; Thomas, A. P. 2-Anilino-Pyrimidine Derivatives as Cyclin Depenedent Kinase Inhibitors. WO 02/096887, December 5, 2002.
128. Chu, X. J.; DePinto, W.; Bartkovitz, D.; So, S. S.; Vu, B. T.; Packman, K.; Lukacs, C.; Ding, Q.; Jiang, N.; Wang, K.; Goelzer, P.; Yin, X.; Smith, M. A.; Higgins, B. X.; Chen, Y.; Xiang, Q.; Moliterni, J.; Kaplan, G.; Graves, B.; Lovey, A.; Fotouhi, N. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4- ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a Potent and Selective Cyclin-Dependent Kinase Inhibitor with Significant in vivo Antitumor Activity. J. Med. Chem. 2006, 49(22), 6549-6560.
129. DePinto, W.; Chu, X. J.; Yin, X.; Smith, M.; Packman, K.; Goelzer, P.; Lovey, A.; Chen, Y.; Qian, H.; Hamid, R.; Xiang, Q.; Tovar, C.; Blain, R.; Nevins, T.; Higgins, B.; Luistro, L.; Kolinsky, K.; Felix, B.; Hussain, S.; Heimbrook, D. In vitro and in vivo Activity of R547: a Potent and Selective Cyclin-Dependent Kinase Inhibitor Currently in Phase I Clinical Trials. Mol. Cancer Ther. 2006, 5(11), 2644-2658.
130. Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. Indirubin and Meisoindigo in the Treatment of Chronic Myelogenous Leukemia in China. Leuk. Lymphoma 2002, 43(9), 1763-1768.
131. Hoessel, R.; LeClerc, S.; Endicott, J. A.; Nobel, M. E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the Active Constituent of a Chinese Antileukaemia Medicine, Inhibits Cyclin-Dependent Kinases. Nat. Cell Biol. 1999, 1(1), 60-67.
132. Marko, D.; Schatzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of Cyclin-Dependent Kinase 1 (CDK1) by Indirubin Derivatives in Human Tumour Cells. Br. J. Cancer 2001, 84(2), 283-289.
133. Kosmopoulou, M. N.; Leonidas, D. D.; Chrysina, E. D.; Bischler, N.; Eisenbrand, G.; Sakarellos, C. E.; Pauptit, R.; Oikonomakos, N. G. Binding of the Potential Antitumour Agent Indirubin-5-sulphonate at the Inhibitor Site of Rabbit Muscle Glycogen Phosphorylase b. Comparison with Ligand Binding to pCDK2/cyclin A Complex. Eur. J. Biochem. 2004, 271(11), 2280-2290.
134. Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-Mitotic Properties of Indirubin-3′-monoxime, a CDK/GSK-3 Inhibitor: Induction of Endoreplication Following Prophase Arrest. Oncogene 2001, 20(29), 3786-3797.
135. Perabo, F. G.; Frossler, C.; Landwehrs, G.; Schmidt, D. H.; von Rucker, A.; Wirger, A.; Muller, S. C. Indirubin-3′-monoxime, a CDK Inhibitor Induces Growth Inhibition and Apoptosis-Independent Up-regulation of Survivin in Transitional Cell Cancer. Anticancer Res. 2006, 26(3A), 2129-2135.
136. Zhang, B.; Tan, V. B.; Lim, K. M.; Tay, T. E.; Zhuang, S. Study of the Inhibition of Cyclin-Dependent Kinases with Roscovitine and Indirubin-3′- oxime from Molecular Dynamics Simulations. J. Mol. Model. 2007, 13(1), 79-89.
137. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural Basis for the Synthesis of Indirubins as Potent and Selective inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases. J. Med. Chem. 2004, 47(4), 935-946.
138. Ribas, J.; Bettayeb, K.; Ferandin, Y.; Knockaert, M.; Garrofe-Ochoa, X.; Totzke, F.; Schachtele, C.; Mester, J.; Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L. Boix, J.; Meijer, L. 7-Bromoindirubin-3'-oxime Induces Caspase-Independent Cell Death. Oncogene 2006, 25(47), 6304-6318.
139. Beauchard, A.; Ferandin, Y.; Frere, S.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thierya, V.; Bessona, T. Synthesis of Novel 5-Substituted Indirubins as Protein Kinases Inhibitors. Bioorg. Med. Chem. 2006, 14(18), 6434-6443.
140. Samanta, S.; Debnath, B.; Basu, A.; Gayen, S.; Srikanth, K.; Jha, T. Exploring QSAR on 3-Aminopyrazoles as Antitumor Agents for their Inhibitory Activity of CDK2/cyclin A. Eur. J. Med. Chem. 2006, 41(10), 1190-1195.
141. Pevarello, P.; Brasca, M. G.; Amichi, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G. P.; Pesenti, F.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A. 3-Aminopyrazole Inhibitors of CDK2/cyclin A as Antitumor Agents. 1. Lead Finding. J. Med. Chem. 2004, 47(13), 3367-3380.
142. Pevarello, P.; Brasca, M. G.; Orsini, P.; Traquandi, G.; Longo, A.; Nesi, M.; Orzi, F.; Piutti, C.; Sansonna, P.; Varasi, M.; Cameron, A.; Vulpetti, A.; Roletto, F.; Alzani, R.; Ciomei, M.; Albanese, C.; Pastori, W.; Marsiglio, A.; Pesenti, E.; Fiorentini, F.; Bischoff, J. R.; Mercurio, C. 3-Aminopyrazole Inhibitors of CDK2/cyclin A as Antitumor Agents. 2. Lead Optimization. J. Med. Chem. 2005, 48(8), 2944-2956.
143. Nesi, M.; Borghi, D.; Brasca, M. G.; Fiorentini, F.; Pevarello, P. A Practical Synthesis of the Major 3-Hydroxy-2-pyrrolidinone Metabolite of a Potent CDK2/cyclin A Inhibitor. Bioorg. Med. Chem. Lett. 2006, 16(12), 3205-3208.
144. Nugiel, D. A.; Etzkorn, A. M.; Vidwans, A.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Cox, S.; Czerniak, P. M.; Doleniak, D.; Seitz, S. P. Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors. J. Med. Chem. 2001, 44(9), 1334-1336.
145. Nugiel, D. A.; Vidwans, A.; Etzkorn, A. M.; Rossi, K. A.; Benfield, P. A.; Burton, C. R.; Cox, S.; Doleniak, D.; Seitz, S. P. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern. J. Med. Chem. 2002, 45(24), 5224-5232.
146. Singh, S. K.; Dessalew, N.; Bharatam, P. V. 3D-QSAR CoMFA Study on Indenopyrazole Derivatives as Cyclin-Dependent Kinase 4 (CDK4) and Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. Eur. J. Med. Chem. 2006, 41(11), 1310-1319.
147. 1,2. J. Med. Chem. 2002, 45(24), 5233-5248.
148. Kim, K.; Kimball, S. D.; Misra, R. N.; Rawlins, D. B.; Hunt, J. T.; Xiao, H. Y.; Lu, S.; Qian, L.; Han, W. C.; Shan, W.; Mitt, T.; Cai, Z. W.; Poss, M. A.; Zhu, H.; Sack, J. S.; Tokarski, J. S.; Chang, C. Y.; Pavletich, N.; Kamath, A.; Humphreys, W. G.; Marathe, P.; Bursuker, I.; Kellar, K. A.; Roongta, U.; Batorsky, R.; Mulheron, J. G.; Bol, D.; Fairchild, C. R.; Lee, F. Y.; Webster, K. R. Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. J. Med. Chem. 2002, 45(18), 3905-3927.
149. Dessalew, N.; Bharatama, P. V.; Singh, S. K. 3D-QSAR CoFMA Study on Aminothiazole Derivatives as Cyclin-Dependent Kinase 2. QSAR & Combinatorial Science 2006, 26(1), 85-91.
150. Misra, R. N.; Xiao H. Y.; Kim, K. S.; Lu, S.; Han W. C.; Barbosa, S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian, L.; Chen, B. C.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron, J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S. A.; Sack, J. S.; Tokarski, J. S; Pavletich, N. P.; Lee, F. Y.; Webster, K. R.; Kimball, S. D. N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent. J. Med. Chem. 2004, 47(7), 1719-1728.
151. Vulpetti, A.; Casale, E.; Roletto, F.; Amici, R.; Villa , M.; Pevarello, P. Structure-Based Drug Design to the Discovery of New 2-Aminothiazole CDK2 Inhibitors. J. Mol. Graphics Modell. 2006, 24(5), 341-348.
152. Pevarello P.; Amici, R.; Villa, M.; Salom, B.; Vulptti, A.; Varasi, M.; Brasca, M. G.; Traquandi, G.; Nesi, M. Phenylacetamido-Thiazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents. WO 03/008365, January 30, 2003.
153. Chu, X. -J.; Ding, Q.; Jiang, N.; Kim, K.; Lovey, A. J.; McComas, W. W.; Mullin, J. G. Jr.; Tilley, J. W. Diaminothiazoles. WO 03/097048 A1, November 27, 2003.
154. Chong, W. K. M.; Duvadie, R. K. Pyrazole-Thiazole Compounds, Pharmaceutical Compositions Containing them, and Methods of their Use for Inhibiting Cyclin-Dependent Kinases. WO 02/12250, February 14, 2002.
155. Huang, J. W.; Shiau, C. W.; Yang, J.; Wang, D. S.; Chiu, H. C.; Chen, C. Y.; Chen, C. S. Development of Small-Molecule Cyclin D1-Ablative Agents. J. Med. Chem. 2006, 49(15), 4684-4689.
156. Shimamura, T.; Shibata, J.; Kurihara, H.; Mita, T.; Otsuki, S.; Sagara, T.; Hirai, H.; Iwasawa, Y. Identification of Potent 5-Pyrimidinyl-2- aminothiazole CDK4, 6 Inhibitors with Significant Selectivity over CDK1, 2, 5, 7, and 9. Bioorg. Med. Chem. Lett. 2006, 16(14), 3751-3754.
157. Kunick, C.; Schultz, C.; Lemcke, T.; Zaharevitz, D. W.; Gussio, R.; Jalluri, R. K.; Sausville, E. A.; Leost, M.; Meijer, L. 2-Substituted Paullones: CDK1/Cyclin B-Inhibiting Property and in vivo Antiproliferative Activity. Bioorg. Med. Chem. Lett. 2000, 10(6), 567-569.
158. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F. S.; Lemcke, T. Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones. J. Med. Chem. 2004, 47(1), 22-36.
159. Pies, T.; Schaper, K. J.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Meijer, L.; Kunicke, C. CDK1-Inhibitory Activity of Paullones Depends on Electronic Properties of 9-Substituents. Arch. Pharm. Pharm. Med. Chem. 2004, 337(9), 486-492.
160. Lahusen, T.; De Siervi, A.; Kunick, C.; Senderowicz, A. M. Alsterpaullone, a Novel Cyclin-Dependent Kinase Inhibitor, Induces Apoptosis by Activation of Caspase-9 Due to Perturbation in Mitochondrial Membrane Potential. Mol. Carcinog. 2003, 36(4), 183-194.
161. Xie, X.; Lemcke, T.; Gussio, R.; Zaharevitz, D. W.; Leost, M.; Meijer, L.; Kunick, C. Epoxide-Containing Side Chains Enhance Antiproliferative Activity of Paullones. Eur. J. Med. Chem. 2005, 40(7), 655-661.
162. Brault, L.; Migianu, E.; Neguesque, A.; Battaglia, E.; Bagrel, D.; Kirsch, G. New Thiophene Analogues of Kenpaullone: Synthesis and Biological Evaluation in Breast Cancer Cells. Eur. J. Med. Chem. 2005, 40(8), 757-763.
163. Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. 1-Azakenpaullone is a Selective Inhibitor of Glycogen Synthase Kinase-3β. Bioorg. Med. Chem. Lett. 2004, 14(2), 413-416.
164. Cimino, G.; De Rosa, S.; De Stefano, S.; Mazzarella, L.; Puliti, R.; Sodano, G. Isolation and X-ray Crystal Structure of a Novel Bromo Compound from Two Marine Sponges. Tetrahedron Lett. 1982, 23(7), 767-768.
165. Schmitz, F. J.; Gunasekera, S. P.; Lakshmi, V.; Tillekeratne, L. M. V. Marine Natural Products: Pyrrololactams from Several Sponges. J. Nat. Prod. 1985, 48(1), 47-53.
166. Meijer, L.; Thunnissen, A. -M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. -H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. -Z.; Biernat, J.; Mandelkow, E. -M.; Kim, S. -H.; Pettit, G. R. Inhibition of Cyclin-Dependent Kinases, GSK-3β and CK1 by Hymenialdisine, a Marine Sponge. Chem. Biol. 2000, 7(1), 51-63.
167. Tasdemir, D.; Mallon, R.; Greenstein, M.; Feldberg, L. R.; Kim, S. C.; Collins, K.; Wojciechowicz, D.; Mangalindan, G. C.; Concepción, G. P.; Harper, M. K.; Ireland, C. M. Aldisine alkaloids from the Philippine Sponge Stylissa massa are Potent Inhibitors of Mitogen-Activated Protein Kinase Kinase-1 (MEK-1). J. Med. Chem. 2002, 45(2), 529-532.
168. Wan, Y.; Hur, W.; Cho, C. Y.; Liu, Y.; Adrian, F. J.; Lozach, O.; Bach, S.; Mayer, T.; Fabbro, D.; Meijer, L.; Gray, N. S. Synthesis and Target Identification of Hymenialdisine Analogs. Chem. Biol. 2004, 11(2), 247-259.
169. Kitagawa, M.; Okabe, T.; Ogino, H.; Matsumoto, H.; Suzuki-Takahashi, I.; Kokubo, T.; Higashi, H.; Saitoh, S.; Taya, Y.; Yasuda, H. Butyrolactone I, a Selective Inhibitor of CDK2 and Cdc2 Kinase. Oncogene 1993, 8(9), 2425-2432.
170. Brana, M. F.; Garcia, M. L.; Lopez, B.; de Pascual-Teresa, B.; Ramos, A.; Pozuelo, J. M.; Dominguez, M. T. Synthesis and Biological Evaluation of Analogues of Butyrolactone I and Molecular Model of its Interaction with CDK2. Org. Biomol. Chem. 2004, 2(13), 1864-1871.
171. WAF1/CIP1 expression. Cell Cycle 2002, 1(1), 90-96.
172. Toogood, P. L. Cyclin-Dependent Kinase Inhibitors for Treating Cancer. Med. Res. Rev. 2001, 6, 487-498.
173. Cui, C. -B.; Ubukata, M.; Kakeya, H.; Onuse, R.; Okada, I.; Takahashi, K.; Isono, K.; Osada, H. Acetophthalidin, a Novel Inhibitor of Mammalian Cell Cycle, Produced by a Fungus Isolated from a Sea Sediment. J. Antibiot. (Tokyo) 1996, 49(2), 216-219.
174. Nomoto, S.; Mori, K. Synthetic Microbial Chemistry. Part 30. Synthesis of Acetophthalidin, a Fungal Metabolite which Inhibits the Progression of the Mammalian Cell Cycle. Liebigs Ann. Recl. 1997, 4, 721-723.
175. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A Novel Approach for the Development of Selective CDK4 Inhibitors: Library Design Based on Locations of CDK4 Specific Amino Acid Residues. J. Med. Chem. 2001, 44(26), 4628-4640.
176. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent CDK4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem. 2001, 44(26), 4615-4627.
177. Kawanishi, N.; Sugimoto, T.; Shibata, J.; Nakamura, K.; Masutani, K.; Ikuta, M.; Hirai, H. Structure-Based Drug Design of a Highly Potent CDK1,2,4,6 Inhibitor with Novel Macrocyclic Quinoxalin-2-one Structure. Bioorg. Med. Chem. Lett. 2006, 16(19), 5122-5126.
178. El-Bayoumy, K.; Sinha, R. Molecular Chemoprevention by Selenium: a Genomic Approach. Mutat. Res. 2005, 591(1-2), 224-236.
179. Sinha, R.; Medina, D. Inhibition of CDK2 Kinase Activity by Methylselenocysteine in Synchronized Mouse Mammary Epithelial Tumor Cells. Carcinogenesis 1997, 18(8), 1541-1547.
180. Zeng, H. Selenite and Selenomethionine Promote HL-60 Cell Cycle Progression. J. Nutr. 2002, 132(4), 674-679.
181. Narayanan, B. A. Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets. Current Cancer Drug Targets 2006, 6(8), 711-727.
182. Mahale, S.; Aubry, C.; Jenkins, P. R.; Marechal, J. D.; Sutcliffe, M. J.; Chaudhuri, B. Inhibition of Cancer Cell Growth by Cyclin Dependent Kinase 4 Inhibitors Synthesized Based on the Structure of Fascaplysin. Bioorg. Chem. 2006, 34(5), 287-297.
183. Brana, M. F.; Cacho, M.; Garcia, M. L.; Mayoral, E. P.; Lopez, B.; de Pascual-Teresa, B.; Ramos, A.; Acero, N.; Llinares, F.; Munoz-Mingarro, D.; Lozach, O.; Meijer, L. Pyrazolo[3,4-c]pyridazines as Novel and Selective Inhibitors of Cyclin-Dependent Kinases. J. Med. Chem. 2005, 48(22), 6843-6854.
184. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase. J. Med. Chem. 2000, 43(1), 133-138.
185. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J. M.; Meijer, L. Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. J. Med. Chem. 2003, 46(2), 222-236.
186. Bettayeb, K.; Tirado, O. M.; Marionneau-Lambot, S.; Ferandin, Y.; Lozach, O.; Morris, J. C.; Mateo-Lozano, S.; Drueckes, P.; Schächtele, C.; Kubbutat, M. H.; Liger, F.; Marquet, B.; Joseph, B.; Echalier, A.; Endicott, J. A.; Notario, V.; Meijer, L. Meriolins, a New Class of Cell Death Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases. Cancer Res. 2007, 67(17), 8325-8334.
187. Supuran, C. T. Indisulam: an Anticancer Sulfonamide in Clinical Development. Expert Opin. Investig. Drugs. 2003, 12(2), 283-287.
188. Fukuoka, K.; Usuda, J.; Iwamoto, Y.; Fukumoto, H.; Nakamura, T.; Yoneda, T.; Narita, N.; Saijo, N.; Nishio, K. Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells. Invest. New Drugs 2001, 19(3), 219-227.
189. Owa, T.; Yoshino, H.; Okauchi, T.; Okabe, T.; Ozawa, Y.; Hata Sugi, N.; Yoshimatsu, K.; Nagasu, T.; Koyanagi, N.; Kitoh, K. Synthesis and Biological Evaluation of N-(7-indolyl)-3-pyridinesulfonamide Derivatives as Potent Antitumor Agents. Bioorg. Med. Chem. Lett. 2002, 12(16), 2097-2100.
190. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic Anhydrase Inhibitors: E7070, a Sulfonamide Anticancer Agent, Potently Inhibits Cytosolic Isozymes I and II, and Transmembrane, Tumor-Associated Isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14(1), 217-223.
191. Talbot, D. C.; von Pawel, J.; Cattell, E.; Yule, S. M.; Johnston, C.; Zandvliet, A. S.; Huitema, A. D.; Norbury, C. J.; Ellis, P.; Bosquee, L.; Reck, M. A. Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Clin. Cancer Res. 2007, 13(6), 1816-1822.
192. Lin, R.; Connolly, P. J.; Huang, S.; Wetter, S. K.; Lu, Y.; Murray, W. V.; Emanuel, S. L.; Gruninger, R. H.; Fuentes-Pesquera, A. R.; Rugg, C. A.; Middleton, S. A.; Jolliffe, L. K. 1-Acyl-1H-[1,2,4] triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis and Evaluation of Biological Activities. J. Med. Chem. 2005, 48(13), 4208-4211.
193. Emanuel, S.; Rugg, C. A.; Gruninger, R. H.; Lin, R.; Fuentes-Pesquera, A.; Connolly, P. J.; Wetter, S. K.; Hollister, B.; Kruger, W. W.; Napier, C.; Jolliffe, L.; Middleton, S. A. The in vitro and in vivo Effects of JNJ-7706621: a Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases. Cancer Res. 2005, 65(19), 9038-9046.
194. Huang, S.; Connolly, P. J.; Lin, R.; Emanuel, S.; Middleton, S. A. Synthesis and Evaluation of N-acyl Sulfonamides as Potential Prodrugs of Cyclin-Dependent Kinase Inhibitor JNJ-7706621. Bioorg. Med. Chem. Lett. 2006, 16(14), 3639-3641.
195. Seong, Y. S.; Min, C.; Li, L.; Yang, J. Y.; Kim, S. Y.; Cao, X.; Kim, K.; Yuspa, S. H.; Chung, H. H.; Lee, K. S. Characterization of a Novel Cyclin-Dependent Kinase 1 Inhibitor, BMI-1026. Cancer Res. 2003, 63(21), 7384-7391.
196. Jain, R. K.; Duda, D. G.; Clark, J. W.; Loeffler, J. S. Lessons from Phase III Clinical Trials on Anti-VEGF Therapy for Cancer. Nat. Clin. Pract. Oncol. 2006, 3(1), 24-40.